New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single molecule

Expert Opinion on Investigational Drugs

Volumn 22, Issue 12, 2013, Pages 1569-1580

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

2 agonist; Bronchodilator; COPD; Corticosteroid; Inhaled drug; MABA; Muscarinic antagonist

Indexed keywords

ACLIDINIUM BROMIDE; AZD 2115; AZD 3199; AZD 8683; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; GLYCOPYRRONIUM BROMIDE; GSK 961081; INDACATEROL; LAS 190792; LAS 40464; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PF 3429281; PF 4348325; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PT 001; PT 003; PT 005; QVA 149; SALMETEROL; SUN 102; TD 5959; TEI 3252; THRX 198321; THRX 200495; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL;

ABSENCE OF SIDE EFFECTS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG WITHDRAWAL; DRY POWDER INHALER; GOLD THERAPY; HIGH RISK POPULATION; HUMAN; INHALER; METERED DOSE INHALER; MONOTHERAPY; NEBULIZER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; URINE INCONTINENCE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84887665188     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.833182     Document Type: Review

References (56)

1. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64(3):450-504.. Invaluable review of the state of the art.
2. Ohar JA, Donohue JF. Mono-and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med 2010;31(3):321-33. Review focusing on the key treatments for COPD
3. Kaik G. Combined administration of ipratropium bromide (sch 1000) and fenoterol in patients with chronic obstructive airway disease Wien Klin Wochenschr. 1975;87:653-6. First demonstration of the additive bronchodilator effects of the two classes of drug
4. Chrischilles E, Gilden D, Kubisiak J, et al. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: Effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care 2002;8:902-11
5. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115(3):635-41
6. GOLD, Global Strategy for the Diagnosis, Management and Prevention of COPD 20 February 2013.. Document defining the disease and its currently recommended treatments.
7. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013;26(3):307-17.. Up to date review on LAMA developments.
8. van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010;65(12):1086-91. First demonstration that concurrent administration of LABAs and LAMAs produces additive effects.
9. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: The SHINE study. Eur Respir J 2013; [Epub ahead of print].. Full details of a key comparison study.
10. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The enlighten study. Respir Med 2013; [Epub ahead of print]. Full details of a 52 week study.
11. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomized, double-blind, parallel-group study. Lancet Respir Med 2013;1(3):199-209.. The critical comparison of QVA-149 with tiotropium.
12. Mahler DA, Decramer M, DUrzo AD, et al. Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: The blaze study. Am J Respir Crit Care Med 2013;187:A6070
13. Vogelmeir CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): A randomised, double-blind, parallel group study. Lancet Respir Med 2013;1(1):51-60. One of the first key comparisons of LAMA/LABA and ICS/LABA combinations.
14. Donohoe JF, Maleki-Yazedi M, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 Mcg in COPD: A randomized, placebo-controlled, 24-week study. Am J Respir Crit Care Med 2013;187:A4275
15. Celli BR, Crater G, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 125/25 Mcg in COPD: A randomized, placebo-controlled, 24-week study. Am J Respir Crit Care Med 2013;187:A2435
16. Anzueto A, Decramer M, Kaelin T, et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD. Am J Respir Crit Care Med 2013;187:A4268
17. Boehringer Ingelheim KG, 2012 Annual Report (April 2013)
18. Almirall SA. Almirall and Forest Laboratories announce positive results of a Phase III Study for aclidinium and formoterol combination in COPD. Press Release; 2013
19. Almirall SA. Almirall and Forest Laboratories announce positive results for the second Phase III Study for aclidinium and formoterol combination in COPD. Press Release; 2013
20. Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 2012;28(42):15015-23
21. Pearl Therapeutics. Pearl therapeutics initiates PT003 phase 3 program for the treatment of individuals with moderate-to-severe COPD. Press Release; 2013
22. Reisner C, Gotfried M, Denenberg MB, et al. Low doses of pearl therapeutics LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label spiriva handihaler in a randomized, double-blind, placebo-controlled phase IIb study in patients with COPD. Am J Respir Crit Care Med 2013;187:A2434
23. Rennard S, Fogerty C, Fischer T, et al. Pearl therapeutics combination LAMA/LABA MDI (GFF MDI, PT003) Provides a Significant Benefit on Home Peak Expiratory Flow Rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, spiriva-handihaler-18 g and foradil-aerolizer-12 g in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Am J Respir Crit Care Med 2012;185:A2259
24. Hughes AD, Jones LH. Dual-pharmacology muscarinic antagonist and b agonist molecules for the treatment of chronic obstructive pulmonary disease. Future Med Chem 2011;3(13):1585-605. One of two key reviews on the MABA strategy.
25. Hughes AD, McNamara A, Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and b2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012;51:71-95. One of two key reviews on the MABA strategy.
26. Ray NC, Alcaraz L. Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: A patent review. Expert Opin Ther Pat 2009;19(1):1-12. Review highlighting companies activities in this area.
27. Steinfeld T, Hughes AD, Klein U, et al. THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 2011;79(3):389-99. First pharmacological characterisation of MABAs.
28. McNamara A, Steinfeld T, Pulido-Rios MT, et al. Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and b(2)-adrenoceptor agonist (MABA). Pulm Pharmacol Ther 2012;25(5):357-63
29. Hughes AD, Chin KH, Dunham SL, et al. Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules. Bioorg Med Chem Lett 2011;21(5):1354-8
30. Glaxo Group Ltd. Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester and its use for treating pulmonary disorders. WO-2007090859; 2007
31. A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt), NCT00550225. 2007. Available from: http://clinicaltrials.gov
32. Aiyar J, Steinfeld T, Pulido Rios MT, et al. In vitro characterization of TD 5959: A novel bi functional molecule with muscarinic antagonist and beta2 adrenergic agonist activity. Am J Respir Crit Care Med 2009;179:A4552
33. Pulido Rios MT, McNamara A, et al. TD 5959: A novel bi functional muscarinic antagonist beta2 adrenergic agonist with potent and sustained in vivo bronchodilator activity in guinea pigs. Am J Respir Crit Care Med 2009;179:A6195
34. Wielders PL, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: A trial with GSK961081. Eur Respir J 2013; Epub ahead of print.. The most significant clinical data published in GSK-961081.
35. Bateman ED, Kornmann O, Ambery C, Norris V. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 2013;doi:pii: S1094-5539(13)00089-8
36. Norris V, Ambery C. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Pulm Pharmacol Ther 2013;doi:pii: S1094-5539
37. A single-dose study to investigate the effects of 3 different doses of inhaled AZD2115 in COPD patients. 2011. Available from: http://clinicaltrials. gov NCT01498081
38. AstraZeneca AB, Pulmagen Therapeutics (Synergy) Ltd. New Combinations for the treatment of asthma. WO-2011012897; 2011
39. See Norman P. Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: Evaluation of WO2011141180. Expert Opin Ther Pat 2012;22(2):185-92
40. Chiesi Farmaceutici SpA. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity. WO2012168349; 2012
41. Chiesi Farmaceutici SpA. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity. WO2012168359; 2012
42. Jones LH, Baldock H, Bunnage ME, et al. Inhalation by design: dual pharmacology b-2 agonists/M3 antagonists for the treatment of COPD. Bioorg Med Chem Lett 2011;21(9):2759-63. Pfizers MABA strategy.
43. Patel S, Marshall S, Summerhill S. The in-vitro pharmacology of PF-3429281-A novel inhaled dual antimuscarinic/beta2 adrenoceptor agonist. Eur Respir J 2010;36(Suppl 54):219s
44. Philip J, Gray A, Clarke N, et al. Demonstration of dual pharmacology in vivo of PF-3429281: A novel inhaled dualantimuscarinic/beta2 adrenoceptor agonist. Eur Respir J 2010;36(Suppl 54):218s
45. Hilton L, Osborne R, Kenyon AS, et al. Optimized glucuronidation of dual pharmacology b-2 agonists/M3 antagonists for the treatment of COPD Med. Chem Commun 2011; 2: 870-6
46. Sugiyama H, Nomura J, Hara T. Pharmacological profile of a novel bronchodilator, TEI3252, as bifunctional M3 antagonist and beta2 agonist. Am J Respir Crit Care Med 2010;181:A4436
47. Teijin Pharma Ltd. Quaternary ammonium salt compound. WO2010126025; 2010
48. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono-and combination therapy with tiotropium in patients with COPD: A 6-month study. Respir Med 2008;14:1511-20
49. van Noord JA, Aumann J-L, Janssens E, et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010;14:995-1004
50. Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: The PATHOS study. J Intern Med 2013;273(6):584-94
51. Barnes PJ. Triple inhalers for obstructive airways disease: will they be useful Expert Rev Respir Med 2011;5(3):297-300
52. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;CD008532
53. A study to assess the systemic exposure, systemic pharmacodynamics and safety and tolerability of fluticasonefuroate, umeclidinium and vilanterol in healthy subjects; NCT01691547. Available from: http://clinicaltrials.gov
54. Chiesi Farmaceutici SA, Annual Report. 2012. Available from: http://www. chiesigroup.com/web/guest/chi-siamo/key-figures/report-finanziariidt=5790)
55. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013;14:49. Useful review of recent developments.
56. Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004;17(1):35-9